
The authorization covers adults who have received at least one prior treatment, while a joint review of clinical benefit remains unfinished.
The European Commission has authorized Daraxonrasib for adults with metastatic pancreatic cancer who have received at least one previous treatment. The drug is intended as an option for patients whose current treatment choices are inadequate.
The European Medicines Agency completed its scientific review through an accelerated, rolling assessment and issued a positive opinion. The Commission said safety, quality and efficacy standards were maintained during the process.
A joint review of the drug’s clinical benefits is not yet complete. The Commission said a report is targeted for December, as work continues to support patient access across Europe.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.